View : 137 Download: 0

When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study

Title
When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study
Authors
Yu, Hee TaeShim, JaeminPark, JunbeomKim, Tae-HoonUhm, Jae-SunKim, Ong-YounJoung, BoyoungLee, Moon-HyoungKim, Young-HoonPak, Hui-Nam
Ewha Authors
박준범
SCOPUS Author ID
박준범scopus
Issue Date
2019
Journal Title
EUROPEAN HEART JOURNAL
ISSN
0195-668XJCR Link

1522-9645JCR Link
Citation
EUROPEAN HEART JOURNAL vol. 40, no. 19, pp. 1531 - 1537
Keywords
Atrial fibrillationCatheter ablationNon-vitamin K antagonist oral anticoagulantBleeding
Publisher
OXFORD UNIV PRESS
Indexed
SCIE; SCOPUS WOS
Document Type
Article
Abstract
Aims Although a recent expert consensus statement has recommended periprocedural uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) as a Class I indication, there have been no clear randomized trials. We investigated the safety and efficacy of UI, procedure day single-dose skipped (SDS), and 24-hour skipped (24S) NOACs in patients undergoing AF ablation. Methods and results In this prospective, open-label, randomized multicentre trial, 326 patients (75% male, 58 +/- 11 years old) scheduled for AF catheter ablation were randomly assigned in a 1:1:1 ratio to UI, SDS, and 24S at three tertiary hospitals. Bridging with low molecular weight heparin was carried out in the patients with persistent AF who were assigned to the 24S group. Dabigatran, rivaroxaban, and apixaban were assigned in order after randomization. The primary endpoint was the incidence of bleeding events within 1 month after ablation. The secondary endpoints included thrombo-embolic and other procedure-related complications. The intra-procedural heparin requirement was higher in the 24S group than others (P < 0.001), and the mean activated clotting time was comparable among the groups (P = 0.139). The incidence of major bleeding up to 1 month after ablation and a post-procedural reduction in the haemoglobin levels did not significantly differ among the treatment groups and different NOACs (P > 0.05). There were no fatal events or thrombo-embolic complications in all the three groups. Conclusion In patients undergoing AF ablation, UI NOACs and SDS or double dose skipped NOACs had a comparable efficacy and safety, regardless of the type of NOAC.
Show the fulltext
DOI
10.1093/eurheartj/ehy870
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE